Meyka Pro is live. Get 50% off your first 3 months.Get Started →
Meyka Pro banner
Genelux Corporation

Genelux Corporation (GNLX) Stock Overview

Explore Genelux Corporation’s financial performance, market position, analyst ratings, and future outlook.

GNLX●NASDAQ
HealthcareBiotechnology
$2.72
$0.02(0.73%)
U.S. Market opens in 4h 1m

Genelux Corporation (GNLX)

Meyka AI Score

Z

Key Financials

Market Cap122M
P/E Ratio-3.03
EPS (TTM)$-0.85
ROE-1.95%
Fundamental Analysis

AI Price Forecasts

1 Month$2.98
3 Months$3.84
1 Year Target$3.28

GNLX Stock Analysis & Investment Overview (NASDAQ)

Our AI-powered analysis of Genelux Corporation (NASDAQ: GNLX) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B, Genelux Corporation's NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of GNLX on the NASDAQ shows an RSI of 46.24, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $3.28 for the NASDAQ listing.

Key metrics behind Genelux Corporation's NASDAQ-traded stock include a P/E ratio of -3.03 and a market capitalization of 122M. Combined with our AI analysis, these give both institutional and retail investors a clear view of GNLX on the NASDAQ.

Price Performance (NASDAQ: GNLX)

1-Day Change
-0.73%
5-Day Change
2.64%
1-Month Change
-5.88%
3-Month Change
-6.85%
6-Month Change
3.03%
Year-to-Date (YTD) Change
-37.61%
1-Year Change
-20.93%
3-Year Change
-87.84%
5-Year Change
-55.77%
All-Time (Max) Change
-55.77%

Contact Information

https://www.genelux.com
858 483 0024
2625 Townsgate Road, Westlake Village, CA, 91361

Company Facts

260 Employees
IPO DateJan 26, 2023
CountryUS
Actively Trading

Frequently Asked Questions